FDA Approves Asmanex Twisthaler for Asthma

Asmanex Twisthaler contains mometasone furoate, a corticosteroid demonstrating potent antiinflammatory activity. Asmanex Twisthaler is indicated for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older, and is also the only inhaled asthma controller therapy approved for once daily initiation and management of asthma in patients previously treated with bronchodilators alone or inhaled corticosteroids.

Posted: March 2005

Related Articles:

Asmanex (mometasone furoate) FDA Approval History

View comments

Hide
(web4)